Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Clinical and MRI efficacy of sc IFN I?-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. J Neurol 2020 Jan;267(1):64-75

Date

09/29/2019

Pubmed ID

31559532

Pubmed Central ID

PMC6954891

DOI

10.1007/s00415-019-09532-5

Scopus ID

2-s2.0-85074028696   1 Citation

Abstract

This study evaluated efficacy of subcutaneous (sc) interferon beta-1a (IFN I?-1a) 44A A?g 3a????a??weekly (tiw) in patients appearing to transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS). The PRISMS study included 560 patients with RRMS (EDSS 0-5.0;a??a?Ya??2 relapses in previous 2A years), and the SPECTRIMS study included 618 patients with SPMS (EDSS 3.0-6.5 anda??a?Ya??1-point increase in previous 2A years [a?Ya??0.5 point if 6.0-6.5]) randomly assigned to sc IFN I?-1a 44 or 22A A?g or placebo for 2-3A years, respectively. These post hoc analyses examined five subgroups of MS patients with EDSS 4.0-6.0: PRISMS (na??=a??59), PRISMS/SPECTRIMS (na??=a??335), PRISMS/SPECTRIMS with baseline disease activity (na??=a??195; patients with eithera??a?Ya??1 relapse within 2A years before baseline ora??a?Ya??1 gadolinium-enhancing lesion at baseline), PRISMS/SPECTRIMS without baseline disease activity (na??=a??140), and PRISMS/SPECTRIMS with disease activity during the study (na??=a??202). In the PRISMS and PRISMS/SPECTRIMS subgroups, sc IFN I?-1a delayed disability progression, although no significant effect was observed in PRISMS/SPECTRIMS subgroups with activity at baseline or activity during the study (regardless of baseline activity). In the PRISMS/SPECTRIMS subgroup, over year 1 (0-1) and 2 (0-2), sc IFN I?-1a 44A A?g tiw significantly reduced annualized relapse rate (pa??a??a??0.001), and relapse risk (pa??<a??0.05) versus placebo. Similar results were seen for the PRISMS/SPECTRIMS with baseline disease activity subgroup. Subcutaneous IFN I?-1a reduced T2 burden of disease and active T2 lesions in the PRISMS/SPECTRIMS subgroups overall, with and without baseline activity. In conclusion, these post hoc analyses indicate that effects of sc IFN I?-1a 44A A?g tiw on clinical/MRI endpoints are preserved in a patient subgroup appearing to transition between RRMS and SPMS.

Author List

Freedman MS, Brod S, Singer BA, Cohen BA, Hayward B, Dangond F, Coyle PK

Author

Staley A. Brod MD Professor in the Neurology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Female
Humans
Immunologic Factors
Injections, Subcutaneous
Interferon beta-1a
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis, Relapsing-Remitting
Severity of Illness Index